Drug Delivery, Gene Editing, In-Vivo and Licensing

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Drug Delivery

Gene Editing

In-Vivo

Licensing

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics

The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics.

Gene Therapy

Gene Therapy Gene Gene Editing In-Vivo

Start-up aims to advance transformative genetic medicines

Drug Discovery World

FEBRUARY 16, 2023

Challenges remain with current delivery approaches, and genetic medicines applications have been generally restricted to the liver and ex vivo settings. Aera’s technology also includes a licensed therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene editing enzymes.

Genetics

Genetics Medicine Gene Editing In-Vivo

Clinical Research Informer

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics

Start-up aims to advance transformative genetic medicines

Stay Connected